Knowledge and performance gaps exist across the spectrum of invasive mold disease, encompassing risk stratification for prophylaxis, choice of antifungal prophylaxis agent, diagnosis of IMI, selection of first-line therapies for IMIs, and management of breakthrough infections. This interactive activity is designed to assist you in optimizing your strategies for managing invasive molds to improve patient outcomes.
Release Date: 12/31/2018
Expiration Date: 12/30/2019
Estimated Time to Complete the Activity: 2.0 hrs
Media: Interactive, text-based activity
Upon completing this activity, the participant should be better able to:
This activity is directed to specialists in infectious diseases, hospital medicine, hematology/oncology, pathology, medical microbiology, critical care, pharmacy, and surgery, as well as other healthcare providers who manage invasive mycoses.
In support of improving patient care, this activity has been planned and implemented by the Postgraduate Institute for Medicine; Terranova Medica, LLC; and the Mycoses Study Group Education and Research Consortium (MSGERC). Postgraduate Institute for Medicine is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.
The Postgraduate Institute for Medicine designates this enduring material for a maximum of 2 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Postgraduate Institute for Medicine (PIM) requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose any real or apparent conflict of interest (COI) they may have as related to the content of this activity. All identified COI are thoroughly vetted and resolved according to PIM policy. PIM is committed to providing its learners with high quality activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest or a commercial interest.
The following indicates the disclosure declaration information and the nature of those commercial relationships:
John R. Perfect, MD, has the following to disclose:
Thomas F. Patterson, MD, FACP, has the following to disclose:
Francisco M. Marty, MD, has the following to disclose:
The PIM planners and managers have nothing to disclose. The Terranova Medica, LLC planners/writers have nothing to disclose.
Peter G. Pappas, MD, FACP, of the MSGERC, has the following to disclose:
There are no fees for participating and receiving CME/CE credit for this activity. During the period December 31, 2018 through December 30, 2019, participants must read the learning objectives and faculty disclosures and study the educational activity.
If you wish to receive acknowledgment for completing this activity, please follow the steps below:
Internet
To participate, you will need access to a computer (either MAC or PC), tablet, or smart phone, with a Chrome (version 22.0.1229.94 or greater) web browser, Firefox (version 3.6 or greater) web browser or an Internet Explorer (version 8.0 or greater) web browser, JavaScript enabled, connected to the Internet (high speed connection preferred).
Terranova Medica, LLC, and PIM are committed to protecting the privacy of those who choose to participate in activities on funguscme.org. This information below describes our security policies for safeguarding personal information as well as the rationale for collection and use of personal information.
Security/safeguarding personal information
This website has physical and procedural safeguards in place to prevent unauthorized access to personal information used to access this website.
Collection and use of personal information
Terranova Medica, LLC, and PIM do not transfer, sell, or share personal information with outside parties. We will not disclose the information unless required in a legal proceeding.
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications. The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.
Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.
There is no charge for this activity.
Jointly provided by Postgraduate Institute for Medicine; Terranova Medica, LLC; and the Mycoses Study Group Education & Research Consortium.
This activity is supported by independent educational grants from Astellas and Merck & Co., Inc.
For further information, contact Tom Davis by telephone or fax (877-276-4523), or by email (tdavis@terranovamedica.com).
If you have any questions regarding the CME/CE certification for this activity, please contact Postgraduate Institute for Medicine at: inquiries@pimed.com or (303) 799-1930.
Copyright © 2018 PIM, MSGERC, and Terranova Medica.